Methods
This multicenter, observational study included ≥18 year-old patients diagnosed with NVAF from August 2012 through November 2013. Patients with cognitive disorders, postoperative NVAF, or NVAF due to reversible causes, those having myocardial infarction or undergoing any operations within the last 3 months, those who participated in another clinical trial in the last 6 months, and pregnant or breastfeeding females were excluded. The EuroQol five-dimensional (EQ-5D) questionnaire was used to assess QoL at baseline and at the12th months. In comparison of two dependent groups, Wilcoxon Signed-Rank test was used for non-normally distributed numerical variables.
Methods
This multicenter, observational study included ≥18 year-old patients diagnosed with NVAF from August 2012 through November 2013. Patients with cognitive disorders, postoperative NVAF, or NVAF due to reversible causes, those having myocardial infarction or undergoing any operations within the last 3 months, those who participated in another clinical trial in the last 6 months, and pregnant or breastfeeding females were excluded. The EuroQol five-dimensional (EQ-5D) questionnaire was used to assess QoL at baseline and at the12th months. In comparison of two dependent groups, Wilcoxon Signed-Rank test was used for non-normally distributed numerical variables.
Results
The median age of the patients (n=210; males, 57.1%) was 65 years (range, 20-88 years). Of the study group, 61.4% were inpatient. According to AF types, 43.8% had permanent AF, 32.9% had paroxysmal AF, and 23.3% had persistent AF. At baseline, 84.3% were on antithrombotic therapy. The EQ-5D questionnaire scores of the patients are presented in Table.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
